News Release

Cleanascite™ Cited in Study of Metabolic Dysfunction–associated Steatotic Liver Disease

MONMOUTH JUNCTION, NJ , December 9, 2024 -- Biotech Support Group reports on an article, describing the simplicity and efficiency of their lipid clearance sample preparation from plasma for mass spectrometry measurement of intact insulin and C-peptide. The citation is: 

Huneault HE, Lo JS, Bai S, He Z, McPhaul MJ, Bril F, et al. Fasting intact insulin by mass spectrometry is associated with metabolic dysfunction-associated steatotic liver disease in youth . Hepatol Commun. 2024;8: e0582. https://doi.org/10.1097/ HC9.0000000000000582

Metabolic dysfunction–associated steatotic liver disease (MASLD), formerly known as NAFLD, is the most common liver disease in children and is a leading cause of liver-related morbidity and mortality. Fasting intact insulin concentrations can predict metabolic dysfunction–associated steatotic liver disease (MASLD) in adults without diabetes; however, research in youth is limited. This study sought to determine whether fasting intact insulin, measured by liquid chromatography-tandem mass spectrometry, is associated with MASLD in children. The methods describe “Quest Diagnostics Nichols Institute performed measurements of intact insulin and C-peptide… the samples were plated and mixed with the addition of internal standards (bovine insulin and a stable isotopically labeled [13C/15N] C-peptide) and Cleanascite delipidation reagent.” The study indicates that similar to adults, measures of fasting intact insulin alone and in combination with ALT (intact insulin × ALT) are strongly associated with MASLD in children and adolescents. The findings offer promising support for the use of fasting intact insulin and ALT levels as a simple, noninvasive method for diagnosing MASLD in pediatric patients. 

“I am pleased to see another reference highlighting Cleanascite™ use to help remove lipids from plasma, as part of the sample prep workflow in mass spectrometry analysis.” states Swapan Roy, Ph.D., President and Founder of Biotech Support Group.

For more information visit: Cleanascite™ Lipid Removal Reagent and Clarification, at
http://www.biotechsupportgroup.com/Cleanascite-Lipid-Removal-Reagent-p/x2555.htm

Keywords: Lipid depletion, Cleanascite™, Metabolic dysfunction–associated steatotic liver disease (MASLD), intact insulin, C-peptide

About Biotech Support Group LLC

Converging with cultural and technological disruptions forthcoming in healthcare, Biotech Support Group develops methods for cost effective and efficient sample prep essential for these expanding markets. Following a tiered business strategy, the company continues its growth in the consumable research products area supporting the rapidly expanding installation of LC-MS instrument and computational infrastructure. For this market, key products include: AlbuVoid™ and AlbuSorb™ PLUS for albumin & IgG depletion, Cleanascite ™ for lipid adsorption, HemogloBind™ and HemoVoid™ for hemoglobin removal, and NRicher™ for targeted proteomics and family specific proteome enrichment. For more information, go to http://www.biotechsupportgroup.com.

For Business Development , contact: Matthew Kuruc 732-274-2866, mkuruc@biotechsupportgroup.com